Monoamine oxidase B (MAOB) inhibitors
Evidence-based neurology checklist on monoamine oxidase b (maob) inhibitors: Indications They are indicated in early PD with mild motor symptoms They may also be used as adjunctive to Levodopa: they are better than the COMT inhibitors They may also improve depression in PD Safinamide may improve…
Indications
- They are indicated in early PD with mild motor symptoms
- They may also be used as adjunctive to Levodopa: they are better than the COMT inhibitors
- They may also improve depression in PD
- Safinamide may improve moderate dyskinesias
Types and doses
Side effects: of Rasagiline
Contraindications: risk of hypertension
Precautions: risk of serotonin syndrome
References
- Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology 2021; 97:942-957.
- Gray R, Patel S, Ives N, et al. Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy: The PD MED Randomized Clinical Trial. JAMA Neurol 2022; 79:131-140.
- Huang YH, Chen JH, Loh EW, Chan L, Hong CT. The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials. Ther Adv Psychopharmacol 2021; 11:2045125320985993.
- Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 2014; 29:1273-1280.
- Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014; 29:229-237.
- And 6 more. Subscribe to see the full list
